Literature DB >> 6708733

Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys.

J A Aloi, T R Insel, E A Mueller, D L Murphy.   

Abstract

The effects of m-chlorophenylpiperazine (mCPP), a serotonin receptor agonist, on the release of plasma prolactin (PRL), growth hormone (GH), and cortisol in the rhesus monkey were studied. mCPP was administered intravenously at doses of 0.5, 1.5, and 3.0 mg/kg. GH and cortisol were increased significantly at all doses while PRL was significantly increased only following administration of 3.0 mg/kg mCPP. mCPP administration also produced behavioral alterations in each monkey, including sedation, penile erection, and defecation. PRL, GH and behavioral responses to mCPP were completely blocked by pretreatment with the serotonin antagonist metergoline (MTG). However, pretreatment treatment with MTG failed to entirely anagonize the cortisol response to mCPP. These data suggest that mCPP has prominent neuroendocrine and behavioral effects which are mediated, in part, by serotonergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708733     DOI: 10.1016/0024-3205(84)90003-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Authors:  K S Murnane; H L Kimmel; K C Rice; L L Howell
Journal:  Horm Behav       Date:  2011-12-14       Impact factor: 3.587

2.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.

Authors:  D L Murphy; E A Mueller; J L Hill; T J Tolliver; F M Jacobsen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.

Authors:  K S Murnane; W E Fantegrossi; J R Godfrey; M L Banks; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2010-05-13       Impact factor: 4.030

5.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study.

Authors:  R S Kahn; S Wetzler; G M Asnis; M A Kling; R F Suckow; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Long-term administration of m-chlorophenylpiperazine (mCPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion.

Authors:  J Ulrichsen; J S Partilla; E M Dax
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.

Authors:  Eduardo R Butelman; Szymon Rus; Denise S Simpson; Angela Wolf; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2008-07-01       Impact factor: 4.030

9.  Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments.

Authors:  K M Wozniak; C S Aulakh; J L Hill; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors.

Authors:  G A Kennett; G Curzon
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.